Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ras oncogene mutation in multiple myeloma.

A Neri1, J P Murphy, L Cro

  • 1Department of Pathology, College of Physicians and Surgeons, Columbia University, New York, New York 10032.

The Journal of Experimental Medicine
|November 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A network meta-analysis of randomized clinical trials in lenalidomide-exposed or -refractory multiple myeloma patients.

ESMO open·2025
Same author

Outcomes and prognostic indicators in daratumumab-refractory multiple myeloma: a multicenter real-world study of elotuzumab, pomalidomide, and dexamethasone in 247 patients.

ESMO open·2025
Same author

Reggio Emilia (Northern Italy) Interdisciplinary Uveitis Clinic: What We Have Learned in the Last 20 Years.

Ocular immunology and inflammation·2024
Same author

Preliminary assessment of persistent organic pollutants (POPs) in tissues of Risso's dolphin (Grampus griseus) specimens stranded along the Italian coasts.

Marine pollution bulletin·2022
Same author

Transcriptomic landscape of TIMP3 oncosuppressor activity in thyroid carcinoma.

Cancer cell international·2022
Same author

Corrigendum to "Cast iron street furniture: A historical review" [Endeavour 44 (3) (2020) 100721].

Endeavour·2021
Same journal

Retraction: In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation.

The Journal of experimental medicine·2026
Same journal

Intravesical mesothelin-based CAR T cells targeting MUC16 effectively control bladder cancer in preclinical models.

The Journal of experimental medicine·2026
Same journal

Flawed translation triggers oncogenic B-T cell communication.

The Journal of experimental medicine·2026
Same journal

Correction: LCK'ed in: Inborn errors of immunity in LCK reveal how TCR signaling is calibrated.

The Journal of experimental medicine·2026
Same journal

Mechanobiology of inflammation: Pulling the strings of innate immunity.

The Journal of experimental medicine·2026
Same journal

Bile acid retention in efferocytic macrophages shapes their inflammatory status during cholangitis.

The Journal of experimental medicine·2026
See all related articles

Ras oncogenes are activated in multiple myeloma (MM) cases, unlike c-myc oncogenes. This ras activation correlates with poor therapeutic response, suggesting prognostic significance in MM patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • Multiple myeloma (MM) is a hematologic malignancy characterized by uncontrolled plasma cell proliferation.
  • The role of specific oncogenes, such as ras and c-myc, in MM pathogenesis is not fully understood.
  • Previous studies have yielded conflicting results regarding oncogene involvement in MM.

Purpose of the Study:

  • To investigate the frequency and types of activating mutations in ras (H-, K-, and N-ras) and c-myc oncogenes in multiple myeloma.
  • To explore potential correlations between oncogene activation and clinical or pathological characteristics of MM.
  • To determine the prognostic significance of ras oncogene activation in MM patients.

Main Methods:

  • Analysis of DNA from 56 tumor biopsies using polymerase chain reaction (PCR)/oligonucleotide hybridization.

Related Experiment Videos

  • Detection of activating mutations in specific codons of H-, K-, and N-ras genes.
  • Nucleotide sequence analysis of PCR products to characterize base pair changes.
  • Southern blot analysis and PCR sequencing to study c-myc gene alterations.

    • Main Results:

    • Activating ras gene mutations were detected in 32% (18/56) of MM cases, with higher frequency after treatment.
    • N-ras codon 61 was preferentially involved, and heterogeneous base pair changes were observed.
    • No structural alterations of the c-myc gene were found in the studied MM samples.
    • A correlation was observed between the presence of ras oncogenes and a lack of response to therapy.

    Conclusions:

    • Ras oncogenes, but not c-myc, are frequently activated in vivo in multiple myeloma cells.
    • Ras oncogene activation represents a significant early oncogenic alteration in MM.
    • The presence of ras oncogenes may serve as a potential prognostic marker for poor therapeutic response in MM.